Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
October 29, 2015 1:14 PM EDTCowen reiterated an Outperform rating and $216.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's 3Q earnings report. Alexion reported Q3 Soliris sales of $665.4MM vs. consensus $666MME and nonGAAP EPS of $1.16 vs. $1.01E.
Analyst Eric Schmidt commented, "Alexion reported Q3... More
